First Quarter 2018 Investor Presentation

Investor Presentation First three months of 2018 Semaglutide demonstrated superiority on both glucose control and weight loss vs dulaglutide in SUSTAIN 7 trial HbA1c (%) 8.5 8.0 7.5 7.0 6.5 Slide 74 dulaglutide 0.75 mg dulaglutide 1.5 mg semaglutide 0.5 mg semaglutide 1.0 mg Weight loss (kg) 0.0 -2.0 7.1% -4.0 6.9% 6.7%* -6.0 6.4%* -2.3 kg -3.0 kg -4.6 kg* -6.5 kg* 0.0 -8.0 0 4 8 12 16 20 Weeks 24 28 32 36 40 0 4 8 12 16 20 24 28 32 36 40 Weeks * p-value <0.0001 Note: Inclusion criteria: Male or female, age ≥18 years, stable treatment with metformin, HbA1c 7.0-10.5%; from a mean baseline of 8.2% HbA1c changing diabetes® novo nordisk

View entire presentation